Daisuke Gomi 6,500,000 8.44% Capital International KK 3,510,455 4.56% Taiyo Pacific Partners LP 2,924,200 3.80% Taiyo Fund Management LLC 2,189,400 2.84% Pfizer Inc. 1,885,136 2.45% AXA Investment Managers UK Ltd. 1,701,500 2.21% FIL Investments (Japan) Ltd. 1,471,848 1.91% Shinichi Tamura 1,136,400 1.48% 【Norges Bank Investment Management】 993,039 1.29% GO ETF Solutions LLP 931,304 1.21% 0070山師さん@トレード中2019/11/06(水) 20:51:45.67ID:dVkxCYrD0 信用買減の枚数そのままノルウェーバンクがお買い上げ。 0071山師さん@トレード中2019/11/06(水) 20:52:16.79ID:1ztaoXLl0 どこからその保有一覧持ってきたんだ 0072山師さん@トレード中2019/11/06(水) 21:06:48.18ID:CxwzKJRD0 あーいきそ 0073山師さん@トレード中2019/11/06(水) 21:45:15.23ID:mRm3609W0 ※Sosei Heptares Twitter 2時間前:(11/6) "Sosei Heptares Job Opportunity - we are looking to strengthen our Molecular Pharmacology team and are recruiting highly motivated laboratory-based in vitro pharmacologists to join our team."
※Sosei Heptares Jobs Portal: "Scientist / Research Scientist - Molecular Pharmacology". (11/6up) Company Description: Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed on the Tokyo Stock Exchange (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK). Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and initiate development of the most innovative and effective medicines for patients worldwide, utilising our world-leading patent-protected technology and platform. Our primary focus is the discovery, design and in selected cases early clinical development of new medicines originating from our proprietary GPCR targeted StaR technology and SBDD platform capabilities. We are advancing a broad and deep pipeline of in novel medicines across multiple therapeutic areas including neurology, immuno-oncology, gastroenterology and inflammation. Our leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Takeda, Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. Sosei Heptares has approximately 145 employees based at its new facility at Granta Park, Cambridge, UK. The size of the company ensures a transparent linkage between all activities from target to clinic. Position: We are currently looking to strengthen our Molecular Pharmacology team and are now seeking to recruit highly motivated laboratory-based in vitro pharmacologists to join our team. The Molecular Pharmacology team is responsible for both new drug target validation and supporting all drug discovery phases up to pre-clinical candidate (PCC) selection via performing assays to study pathological characteristics of GPCRs in disease. This role will include tasks relating to assay development, provision of routine small/large molecule screening and more detailed mechanism of action studies in native cellular systems. Requirements and Expectations: The successful candidate is expected to have: ・An undergraduate/postgraduate degree in pharmacology or similar biological sciences or relevant industrial experience. ・Practical laboratory experience (such as mammalian cell culture, experience in recombinant cell-based assays). ・Strong numerical and analytical ability. ・Excellent communication and interpersonal skills and demonstrated capability to operate in a collaborative and entrepreneurial environment. ・・・ The posting date is: 6th November 2019. The closing date for applications is 6th December 2019. 0074山師さん@トレード中2019/11/06(水) 21:46:10.89ID:mRm3609W0 ※Sosei Heptares Twitter 2時間前:(11/6) "Sosei Heptares Job Opportunity - we are seeking a commercially minded and motivated Finance Manager with primary responsibility as the process owner for all revenue accounting."
※Sosei Heptares Jobs Portal: "Finance Manager". (11/6up) Company Description: Sosei Group Corporation (trading as Sosei Heptares) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK). Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform. Our primary focus is the discovery, design and development of new medicines originating from its proprietary G Protein-Coupled Receptor (GPCR) targeted StaR technology and Structure Based Drug Design (SBDD) platform capabilities. The company is advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and other rare/specialty diseases. Its leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. Sosei Heptares has approximately 145 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development. Position: We are now seeking to appoint a commercially minded, enthusiastic and motivated Finance Manager to work within our Finance Team. This is an exceptional opportunity to participate in an exciting and fast paced environment. The successful candidate will work independently within a team environment. Their primary responsibility will be to act as the process owner for all Revenue accounting ($75m+ annually): 0075山師さん@トレード中2019/11/06(水) 21:46:46.65ID:mRm3609W0 Requirements: Key Duties: Accounting: ・Calculation of royalty income and management of relationship with our partner, Novartis ・Calculation of accrued / deferred income relating to all contracts ・Ensure all passthrough costs are identified, accrued and billed as appropriate ・Calculation of grant income receivable and support grant claims ・Creation of accounting papers for each new material transaction that examines the application of IFRS 15 to the contract (this may involve seeking specialist advice from your professional advisers) ・Creation of new financial models for revenue deferral / accrual ・Management of the Sales Ledger (including invoicing / month end revaluations / collections) ・Preparation of relevant balance sheet reconciliations ・Own other financial processes ・Ad hoc projects (e.g. IT system upgrades) Forecasting and Planning: ・Revenue forecasts (Year to Go, Annual Plan, 5 Year Plan) Advisory: ・Review draft contracts and advise our Business Development team on deal structures from an IFRS 15 and working capital optimisation perspective ・・・ The closing date for applications is not applicable. 0076山師さん@トレード中2019/11/06(水) 22:30:26.44ID:mRm3609W0 ・・・
Events update: ※Drug Discovery 2019: "Protein Engineering of G-Protein Coupled Receptors Using Directed Evolution in Saccharomyces Cerevisiae": Daniel Jones, Sosei Heptares. (11/6 Today Presented) ※Drug Discovery 2019: "Application of Sosei Heptares GPCR StaR Platform for Structure Based Drug Design & Hit Identification": Greg Osborne, Sosei Heptares. (11/6 Today Presented) ※ペプチドリーム 2019年6月期第1四半期決算 (11/7) ※LIP.横浜オープンイノベーションカンファレンス「クロスイノベーションが創るライフサイエンス産業の未来〜技術革新や新たなアライアンスの創出を目指して〜」ポスター発表:JITSUBO。(11/8 15:10 Presenting) ※富士フイルム 2019年度 第2四半期決算 (11/12) ※Sosei Group 2019年12月期第3四半期決算発表 (11/12) ※Optinose Q3 2019 Results. (11/12) ※AACR Tumor Immunology and Immunotherapy: MiNA Therapeutics. (11/17-20) ※Clinical Trials Europe 2019: "Case Study Magnetic Resonance Imaging Biomarkers in Early Phase Clinical Development: from Patient Selection to Proof of Mechanism": Geor Bakker, Sosei Heptares. (11/20 9:30-10:00 Presenting) ※Clinical Trials Europe 2019: Early Phase Clinical Development Round Table Session: "Table 1: Is biomarker driven early clinical development achieving critical go/no go decisions faster?" Pradeep Nathan, Sosei Heptares. (11/20 16:30 Presenting) ※HBA London Presents Event "Understanding Mindfulness and Compassion: a Cognitive Neuroscience approach" Location: Sosei Heptares Steinmetz Building, Granta Park. (11/27 18:00-20:00 Presenting) ※World BI DDIP (Drug Discovery Innovation Program) Conference 2019: Jonthan Mason, Sosei Heptares. (11/28-29) 0077山師さん@トレード中2019/11/06(水) 22:30:42.12ID:mRm3609W0 ※British Thoracic Society (BTS) Winter Meeting 2019: Novartis. (12/4-6) ※四季報2020年新春号:12月中旬発売 (四季報先取り12月上旬) ※JP Morgan Healthcare Conference 2020: Novartis, MiNA Therapeutics. (1/13-16) ※ASCO Gastrointestinal Cancers Symposium 2020: MiNA Therapeutics. (1/23-25) ※Novartis Q4 and Full Year Results 2019 and Annual Report 2019 Publication. (1/29) ※Patients as Partners Europe: "Patient Involvement in Regulatory Decisions: How Regulations are Incorporating the Patient Voice": Domenico Merante, MD, VP, Clinical Development, Sosei Heptares. (1/27 16:15-16:45 Presenting) ※Sosei Group 2019年12月期決算 (2020年2月発表) ※Astrazeneca Full-Year 2019 Results. (2/14) ※SMi RNA Therapeutics: "Small Activating RNAs(saRNAs) - A Novel Therapeutic Class of Oligonucleotides with Broad Therapeutic Potential": David Blakey, MiNA Therapeutics. (2/19 13:20-14:00 Presenting) ・Description of saRNA technology and broad applicability to a range of therapeutic targets。 ・Update on MiNA’s lead saRNA product MTL-CEBPA - preclinical and clinical data。 ・Emerging data on new therapeutic strategies with saRNAs。 ・・・ 0078山師さん@トレード中2019/11/06(水) 23:01:58.62ID:Bdd2gelr0 長文のせいでジワジワ下がるな おまえだけで半分レスしてんじゃん
お前の中ではな 0118山師さん@トレード中2019/11/07(木) 13:26:09.94ID:fUAB0v210 ノルウェーバンクが100万株か、すごいな 0119山師さん@トレード中2019/11/07(木) 13:50:50.89ID:CWVbD7DeM なぜ信用買が100万株も減ったん? 0120山師さん@トレード中2019/11/07(木) 13:50:52.03ID:2tdOB7lo0 3連敗マイテンしそう 0121山師さん@トレード中2019/11/07(木) 13:51:43.09ID:2tdOB7lo0 そりゃ12勝1負だったし 株価が上がれば信用も経る 0122山師さん@トレード中2019/11/07(木) 14:09:20.06ID:ww0QucbFd マイ転したら追証だわ 0123山師さん@トレード中2019/11/07(木) 14:17:30.35ID:ww0QucbFd おわた 0124山師さん@トレード中2019/11/07(木) 14:20:04.89ID:CoK4aonN0 こんな静かな追証あるわけないだろ! 0125山師さん@トレード中2019/11/07(木) 16:22:35.03ID:uF7rw6jMM 屑だな 0126山師さん@トレード中2019/11/07(木) 17:00:20.31ID:2uUnd09D0 ちなみにCipla Limited Q2 2020 Results: ※Cipla Q2 FY20 Results. Investor Presentation. (11/6) Europe & Emerging Markets: Strengthening portfolio offering in key markets: ・In Sri Lanka, entered into a strategic partnership with Novartis for marketing and distribution of Ultibro Breezhaler. ・Signed a strategic partnership with Novartis, effective October 1, to market their Respiratory portfolio in Australia. ※Cipla Q2 2020 Earnings Call. (11/6) "In emerging markets, we strengthened our portfolio offering in focus markets. In Srilanka, we entered into a strategic partnership with Novartis for marketing and distribution of the Ultibro Breezhaler." "We are pleased to report that we have signed a strategic partnership with Novartis effective October 1st to market the respiratory portfolio in the market." ・・・ 0127山師さん@トレード中2019/11/07(木) 17:00:45.32ID:2uUnd09D0 ※フィスコ:[マザーズ先物概況]:変わらず、個別株物色は活発 。(11/7 15:22) 7日のマザーズ先物は前日比で変わらずの863.0ptとなった。なお、高値は867.0pt、安値は862.0pt、取引高は341枚。 本日のマザーズ先物は、東証1部市場の主力銘柄が冴えない動きの中、直近IPOや直近決算の内容が良好だった企業など個別に材料のあった銘柄を中心に物色が盛んであった。 前日の米国市場では、連日の最高値更新を受けた利益確定の動きのほか、米中首脳会談の開催時期が12月になる見込みであると報じられたことで貿易摩擦解消期待がやや後退し、NYダウは小反落となった。 本日の日経平均は営業損益の赤字が嫌気されたソフトバンクGなどが重石となるかたちで軟調な動きとなり、投資家の関心は中小型株が集まるマザーズ市場に向かった。 また、取引時間中に円高が進行した割には日経平均が底堅かったことなども個人投資家心理の改善に寄与したようだ。 結局、マザーズ先物は上昇一服後はこう着感の強い動きとなったが、売買代金上位銘柄の大幅高などが支えるかたちで前日比変わらずとなった。 売買代金上位では、第1四半期営業損益の黒字転換を好感した流れが続いたホープ、今期営業利益が2ケタ増益を見込むAmaziaがなどが2ケタ台の大幅上昇となった一方で、 直近IPO銘柄のセルソースやジェイック、中村超硬、そーせい、メルカリなどは下落した。 0128山師さん@トレード中2019/11/07(木) 17:01:02.16ID:2uUnd09D0 ※フィスコ:[マザーズ市況] マザーズ指数は反発も、決算発表ピーク前に上値重い。(11/7 16:28) 7日のマザーズ指数は反発となった。前日の米国株式市場で、米中首脳会談の開催時期が12月となる見込みであると報じられたことで貿易摩擦解消期待が後退したなか、円相場も1ドル=109円を割り込んだ。 これを受け、本日のマザーズ市場には朝方からやや売りが先行した。 一方で、決算後の市場反応が注目されていた東証1部のソフトバンクGが急速に下げ幅を縮小したことから、個人投資家のセンチメントにも好影響を与え、マザーズ銘柄に対する買い戻しの動きも散見された。 その後もマザーズ指数はプラス圏での推移となったが、明日の決算発表ラッシュのピークを前に、物色の広がりはみられず、積極的な上値追いには至らなかった。 なお、売買代金は概算で523.99億円。騰落数は、値上がり141銘柄、値下がり141銘柄、変わらず19銘柄となった。 売買代金上位では、セルソースが8%安になったほか、中村超硬、ジェイック、そーせい、サンバイオ、メルカリ、ナノキャリア、ALBERTは軟調。 0129山師さん@トレード中2019/11/07(木) 17:01:20.28ID:2uUnd09D0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 ・・・ ※SOSEIの成長相場の動向:再びの上昇(水準訂正)相場は順調に推移:(12/25:直近最安値748※、1/4:年初来安値_780、8/5:年初来高値:2794)。笑。業績相場への動意待ち。笑。 2018/10/26 (終値_878) 25日線1146.04(-23.39%) ・(10/26安値_844)※10/19:Cambridge R&D Facilities, SoseiHeptares始動 2018/11/30 (終値1105) 25日線1007.20( +9.71%) ・(10/30安値_835) ※11/8:第2四半期決算[11/9ストップ高:終値1135] 2018/12/28 (終値_799) 25日線_948.64(-15.77%) ・(12/25最安値_748) ※12/1:SoseiHeptares本格始動[再びの拾い場※][強気相場からの時間軸調整が終了] 2019/_1/_4 (終値_864) 25日線_940.80( -8.16%) ・(_1/4年初来安値_780) ※1/1:田村CEO復帰※1/7:AZD4635第U相[1/8ストップ高:終値1078] [上昇トレンドへ転換] 2019/_2/_1 (終値1021) 25日線1051.28( -2.88%) ・(_1/30安値_985) ※空売り価格規制トリガー抵触(1/21安値1164, 1/30安値985)※(1/21:高値更新:1360) 2019/_3/_1 (終値1250) 25日線1133.28(+10.83%) ・(_2/_4安値1021) ※2/14:決算 ※2/22:IR説明会(阿倍野)「次なる成長ステージに向けた成長戦略」 2019/_4/_5 (終値1593) 25日線1331.60(+19.63%) ・(_3/11安値1105) ※3/16:中国上市 ※(3/20:高値更新:ストップ高:1526) 2019/_5/10 (終値1486) 25日線1494.08( -0.54%) ・(_4/22安値1372) ※空売りトリガー抵触(4/11安値1400) ※(4/9:高値更新:1717)※(5/15:高値更新:1743) 2019/_6/_7 (終値2014) 25日線1800.28(+11.87%) ・(_5/13安値1429) ※5/14:Pfizer進捗;第1四半期決算 ※5/24:QVM149申請 ※高値更新:(5/22:1834)(5/23:2149)(5/28:2296) 0130山師さん@トレード中2019/11/07(木) 17:02:15.95ID:2uUnd09D0 2019/_7/_5 (終値2338) 25日線2172.52( +7.62%) ・(_6/12安値1969) ※6/10:Pfizer進捗※6/18:IR説明会(仙台) ※高値更新:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482) 2019/_8/_2 (終値2544) 25日線2448.12( +3.92%) ・(_7/_9安値2216) ※7/16:Genentech提携※(7/16ストップ高:高値更新:2773) ※7/18:APP13007進捗 2019/_9/_6 (終値2335) 25日線2463.68( -5.22%) ・(_8/30安値2179) ※8/5:武田薬品提携 ※8/5:年初来高値更新:2794) ※8/13:第2四半期決算 2019/10/_4 (終値2438) 25日線2342.44(+4.08%) ・(_9/17安値2088) ※9/12: R&D Day※9/28:MTL-CEBPA単剤第T相最終結果※9/30:QVM149第V相IRIDIUM結果 2019/10/11 (終値2150) 25日線2347.80( -8.42%) ・(10/11安値2130) ※10/9:Genentech進捗 2019/10/18 (終値2307) 25日線2335.76( -1.23%) ・(10/15安値2139) 2019/10/25 (終値2403) 25日線2354.04(+2.04%) ・(10/21安値2276) ※5日・25日線再GC (10/25) 2019/11/_1 (終値2570) 25日線2385.96(+7.71%) ・(10/28安値2415) ※5日・75日線再GC(10/29) ※6ヶ月・60ヶ月線GC (10/30) ※12ヶ月・24ヶ月線GC(11/1) 2019/11/_5 (終値2531) 25日線2387.40(+6.01%) (安値2528) 2019/11/_6 (終値2519) 25日線2389.80(+5.41%) (安値2480) 2019/11/_7 (終値2513) 25日線2393.40(+5.00%) (安値2511) 0131山師さん@トレード中2019/11/07(木) 17:02:38.62ID:2uUnd09D0 更なる成長の黎明期にて、拾い場(底値)からの水準訂正は、3倍圏ステージにて順調に推移。笑。予定通りに年初来高値を更新。笑。 新生SoseiHeptares、次なる成長ステージに向けた成長戦略も順調。笑。更なる成長期での次なる進捗・展開が楽しみですね。笑。 今回(再び)の上昇相場も面白くなりました。笑。踊り場にて動意待ち。笑。着実な進捗と共に、更なる成長が楽しみですね。笑。 0132山師さん@トレード中2019/11/07(木) 20:13:32.80ID:VO+ogASD0 長文来たな 明日もジワジワ株価が下がるな 0133山師さん@トレード中2019/11/07(木) 20:34:37.18ID:m4Qg1sX90 今年の週足を見るに、4週連続陽線で5週目で上髭陰線のパターンが多いから 決算当日まで上がると期待してたけどなんか厳しそうだね 0134山師さん@トレード中2019/11/07(木) 20:38:33.55ID:lQKMzDDS0 まぁペプチ・そーせいといった典型的な過大評価株の見直し売りはこれから厳しくなるだろうね 本物はサンバイオだけだね 0135山師さん@トレード中2019/11/07(木) 21:30:15.40ID:2uUnd09D0 Heptares Patent update: ・・・ ※米国特許(Heptares):Muscarinic Agonists (US Patent 10351545 B2). (7/16公開) ※米国特許出願(Heptares):CGRP Receptor Antagonists (US20190231773 A1). (8/1公開) ※米国特許出願(Heptares):Mutant G-Protein Coupled Receptors and Methods for Screening Them (US20190241644 A1). (8/8公開) ※米国特許(Heptares):Bicyclic AZA Compounds as Muscarnic M1 Receptor and/or M4 Receptor Antagonists (US Patent 10385039 B2). (8/20公開) ※欧州特許出願(Heptares):Heterocyclic Compounds Having Activity as Modulators of Muscarinic M1 Receptor and/or M4 Receptors in the Treatment of CNS Diseases and Pains (EP3526207 A1). (8/21公開) ※日本特許(Heptares):「変異体タンパク質とその製造方法」(特許第6567291号 B2) (8/9登録、8/28公開) ※米国特許出願(Heptares):Muscarinic Agonists (US 20190270718 A1). (9/5公開) ※米国特許出願(Heptares):Pharmaceutical Compounds (US 20190276437 A1). (9/12公開) ※米国特許(Heptares):Muscarinic M1 Receptor Agonists (US Patent 10413553 B2). (9/17公開) ※米国特許(Heptares):Muscarinic Receptor Agonists (US Patent 10428088 B2). (10/1公開) ※米国特許(Heptares):Assay for Assessing Conformational Stability of Membrane Protein (US Patent 10458993 B2). (10/29公開) 0136山師さん@トレード中2019/11/07(木) 21:30:56.40ID:2uUnd09D0 ↓ ※米国特許出願(Heptares):"Bicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor". (11/7公開) ・Document Type and Number: United States Patent Application 20190337925 A1 ・Publication Date: 2019/11/07 ・Assignee: Heptares Therapeutics Limited. Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein. http://www.freepatentsonline.com/20190337925.pdf0137山師さん@トレード中2019/11/08(金) 00:02:25.55ID:EAu8C3Yy0 HTL0030310 update: ・・・ ※Sosei Heptares:「内分泌障害治療薬として開発中のHTL0030310(選択的SSTR 5受容体作動薬)の第T相臨床試験を開始」本試験は英国にて実施され、最大64例の被験者を対象に安全性、忍容性、薬物動態および薬力学を検討します。中間成績は2019年下期を見込。(2/20) ※Sosei Heptares Official Blog:「自社開発プログラムSSTRが臨床試験入り」臨床試験入りを果たした当社の候補薬としては、6つ目になります。(2/20) ※ClinicalTrials(NCT03847207): Phase 1, A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310: Estimated Primary Completion: "2019/7 ". Estimated Study Completion: "2019/10". (2/20, New Trial Record) ※ClinicalTrials(NCT03847207): Phase 1, A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310: Actual Study Start: "2019/2/13". Status Change: "Recruiting". (2/25update, Recruiting) ※ClinicalTrials(NCT03847207): Phase 1, A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310:. Status Change: "Active, Not recruiting". (5/6update, "Active. No Longer Recruiting") ※ClinicalTrials(NCT03847207): Phase 1, A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310:. Primary Completion Change: 2019/7 → "2020/3". Study Completion Change: 2019/10 → "2020/4". (8/8update) ↓ 0138山師さん@トレード中2019/11/08(金) 00:03:10.08ID:EAu8C3Yy0 ※ClinicalTrials(NCT03847207): Phase 1, A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310. (11/7update, "Recruiting") Study Status: ・Record Verification (Change): November 2019 ・Overall Status (Change): Active, not Recruiting→"Recruiting" ・Estimated Primary Completion (Change): March 2020→"April 2020" ・Estimated Study Completion (Change): April 2020→"May 2020" Study Design: ・Enrollment (Change): 120→"176" [Anticipated] Central Contact: ・Central Contact (Add): "Claire Swann, Quotient Sciences". Locations Status (Change): ・Quotient Sciences, Nottingham, United Kingdom: "Recruiting" ・(Add) "Principal Investigator: Philip Evans, MBChB". 0139山師さん@トレード中2019/11/08(金) 00:30:10.87ID:EAu8C3Yy0 ONCORNET2.0 update: ※Sosei Heptares:創薬「EUトレーニングネットワークONCORNET2.0に積極的に参加」EUがONCORNET2.0に対して400万ユーロの助成金を授与。当社研究所はこれに参加し積極的に研究者を受け入れる。(6/5) ・研究チームは、CXCR4 / ACKR3の制御のための新しいアプローチを開発し、発癌反応に及ぼす影響を調査し、創薬の鍵となる新たな知見とリード化合物創製の可能性を求めます。 ↓ ※Vrije Universiteit Amsterdam (VU): "PhD-Student (3 years) Medicinal Chemistry". (11/7) ・Published: Today. ・Deadline: 31 Dec. ONCORNET2.0, the Marie Skłodowska-Curie European Training Network (ETN), is looking for a highly motivated and talented student with a MSc degree who is interested in an ambitious multidisciplinary project on oncogenic G protein-coupled receptors (GPCRs). Job Description: "Photoactivatable ligand tools for CXCR4 and ACKR3 (ESR1)" Photopharmacology has emerged as an exciting research area on the interface between chemistry and biology. In photopharmacology, light is used to switch biological activity of small-molecule ligands of specific proteins. As such, it provides precise spatiotemporal control of protein activity and is compatible with living systems. Photoswitchable and photocaged ligands are promising research tools to study biological processes and hold promise as potential light-activatable medicines. As part of the broader Oncornet 2.0 consortium, this project aims unleash photopharmacology on the chemokine receptors CXCR4 and ACKR3 by investigating the synthesis and photochemistry of photosensitive small-molecule ligands (http://www.oncornet.eu/index.php/projects). Your duties: ・design, synthesis and chemical analysis of photoswitchable and/or photocaged small-molecule CXCR4 and ACKR3 ligands. ・in-depth photochemical characterization of the synthesized ligands. ・close collaboration with fellow PhD student ESR7 on the in vitro pharmacological characterization of the synthesized ligands. ・collaborations with other fellow PhD students in the consortium on the application of the synthesized ligands. ・execution of two external secondments: one with the company Heptares and one at University Hospital Jena. ・・・ 0140山師さん@トレード中2019/11/08(金) 05:47:06.35ID:z3c29dUX0 HO 0141山師さん@トレード中2019/11/08(金) 07:29:33.51ID:dviPhrBsd>>132 おまえがそれを書きに来るたびに 寿命が縮む呪いをかけといた 0142山師さん@トレード中2019/11/08(金) 07:31:56.99ID:NHHBZuKnd 空売りガイジってまだいるの? あぼんしてて見れないだけ? 0143山師さん@トレード中2019/11/08(金) 07:41:02.31ID:yYayNzVSM まぁ昨日騒がれた空売り屋のペプチ批評。まんざら間違ってないな。13年間で上市製品ひとつもなし。それでも東一行って、時価総額そーせいの3倍。そりゃ空売りされるわ。